Drug Information

Drug General Information
Drug ID
D04HOT
Former ID
DIB010449
Drug Name
LFG-316
Drug Type
Antibody
Indication Macular degeneration [ICD9: 362.5; ICD10:H35.3] Phase 2 [523790]
Company
Novartis AG
Target and Pathway
Target(s) Complement C5 Target Info [544404]
KEGG Pathway Complement and coagulation cascades
Prion diseases
Pertussis
Staphylococcus aureus infection
Herpes simplex infection
Systemic lupus erythematosus
Reactome Activation of C3 and C5
Peptide ligand-binding receptors
G alpha (i) signalling events
Regulation of Complement cascade
WikiPathways Complement Activation, Classical Pathway
Human Complement System
Spinal Cord Injury
Allograft Rejection
GPCR ligand binding
GPCR downstream signaling
Complement cascade
References
Ref 523790ClinicalTrials.gov (NCT01527500) Intravitreal LFG316 in Patients With Age-related Macular Degeneration (AMD). U.S. National Institutes of Health.
Ref 544404Advances in the management of macular degeneration. F1000Prime Rep. 2014; 6: 29.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.